Everolimus delayed and suppressed cytomegalovirus DNA synthesis, spread of the infection, and alleviated cytomegalovirus infection

Tan, Lei; Sato, Noriaki; Shiraki, Atsuko; Yanagita, Motoko; Yoshida, Yasuhiko; Takemura, Y; Shiraki, Kimíyasu

doi:10.1016/j.antiviral.2018.12.004

Cited by 24 publications

(16 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, since hyper-reactivity is one of the determinants of COVID-19 critical phase, Everolimus could be utilized for the same rational use as Tocilizumab, Hydrochloroquine, Heparin, and Steroids in the intensive therapy of COVID-19 (Askanase et al, 2020;Chen et al, 2020;Geng et al, 2020;Li et al, 2020;Nikolich-Zugich et al, 2020;Piva et al, 2020;Qin et al, 2020;Radbel et al, 2020;Whyte et al, 2020;Ye et al, 2020;Yuki et al, 2020;Zhao, 2020). Moreover, the putative anti-replicative effect of Everolimus in controlling viral spread could also be promising in SARS-CoV2 infection (Figure 1) on the basis of its ability to reduce mRNA translation, ribosome biogenesis, protein synthesis, mitochondrial metabolism, and viral replication (Dunlop and Tee, 2009;Laplante and Sabatini, 2009;Dowling et al, 2010;Garofalo et al, 2019;Nanmoku et al, 2019;Tan et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, Everolimus has surprisingly been associated with the reduction of viral replication of CMV, BKV, and HCV post-transplantation and in cancer patients (Garofalo et al, 2019;Nanmoku et al, 2019;Tan et al, 2019), although the specific drug mechanism has never been definitively clarified. In this regard, the combination of antiviral drugs like leflunomide and fluoroquinolones/Everolimus should favor BKV viremia clearance (Garofalo et al, 2019), and the conversion from conventional immunosuppressant drugs to Everolimus appears to induce the remission of EBV-related lymphoproliferative disorder in kidney transplantation patients (Nanmoku et al, 2019).…”

Section: The Observed Hyperactivation Of the Immune Response In Covidmentioning

confidence: 99%

“…In this regard, the combination of antiviral drugs like leflunomide and fluoroquinolones/Everolimus should favor BKV viremia clearance (Garofalo et al, 2019), and the conversion from conventional immunosuppressant drugs to Everolimus appears to induce the remission of EBV-related lymphoproliferative disorder in kidney transplantation patients (Nanmoku et al, 2019). Moreover, Everolimus has been described to effectively inhibit in vitro CMV replication in infected cells (Tan et al, 2019).…”

Section: The Observed Hyperactivation Of the Immune Response In Covidmentioning

confidence: 99%

See 2 more Smart Citations

An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?

et al. 2020

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: The Observed Hyperactivation Of the Immune Response In Covidmentioning

confidence: 99%

Section: The Observed Hyperactivation Of the Immune Response In Covidmentioning

confidence: 99%

See 1 more Smart Citation

An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?

et al. 2020

View full text Add to dashboard Cite

“…Modifying the AEDs of patients with wellcontrolled seizures because of seizure exacerbations or status epilepticus may raise the risk of COVID-19. In clinical settings, therefore, medications must be chosen on an individual basis [28].…”

Section: Epilepsymentioning

confidence: 99%

Chronic neurological diseases and COVID-19: Associations and considerations

Meshkat

Salimi

Joshaghanian

et al. 2020

Translational Neuroscience

View full text Add to dashboard Cite

The 2019 novel coronavirus pandemic, severe acute respiratory syndrome CoV-2 (COVID-19), has been a worldwide urgent public health threat, resulting in six-hundred seventy thousand deaths to date. The COVID-19 pandemic has led to a series of public health challenges. One such challenge is the management of diseases such as chronic neurological diseases during an epidemic event. COVID-19 affects all kinds of people, including older people with chronic underlying diseases, who are particularly at risk of severe infection or even death. Chronic neurological diseases such as epilepsy, dementia, Parkinson’s disease (PD), and multiple sclerosis (MS) are frequently associated with comorbidities; thus, these patients are in the high-risk category. Therefore, in this article, we review associations and challenges the people with epilepsy, dementia, PD, and MS faces during the COVID-19 pandemic and suggest approaches to provide consensus recommendations on how to provide the best possible care.

show abstract

“…The success of mammalian target of rapamycin (mTOR) inhibitors in reducing HCMV disease in transplant patients may encourage further studies on the potential of cellular protein kinase inhibitors for therapy of herpesvirus-associated diseases [86,87,88]. Recently, everolimus was shown to delayed and suppress DNA synthesis, spread of the infection, and alleviated cytomegalovirus infection [89].…”

Section: Cellular Targetsmentioning

confidence: 99%

Novel Therapeutics for Epstein–Barr Virus

2019

View full text Add to dashboard Cite

Epstein–Barr virus (EBV) is a human γ-herpesvirus that infects up to 95% of the adult population. Primary EBV infection usually occurs during childhood and is generally asymptomatic, though the virus can cause infectious mononucleosis in 35–50% of the cases when infection occurs later in life. EBV infects mainly B-cells and epithelial cells, establishing latency in resting memory B-cells and possibly also in epithelial cells. EBV is recognized as an oncogenic virus but in immunocompetent hosts, EBV reactivation is controlled by the immune response preventing transformation in vivo. Under immunosuppression, regardless of the cause, the immune system can lose control of EBV replication, which may result in the appearance of neoplasms. The primary malignancies related to EBV are B-cell lymphomas and nasopharyngeal carcinoma, which reflects the primary cell targets of viral infection in vivo. Although a number of antivirals were proven to inhibit EBV replication in vitro, they had limited success in the clinic and to date no antiviral drug has been approved for the treatment of EBV infections. We review here the antiviral drugs that have been evaluated in the clinic to treat EBV infections and discuss novel molecules with anti-EBV activity under investigation as well as new strategies to treat EBV-related diseases.

show abstract

Everolimus delayed and suppressed cytomegalovirus DNA synthesis, spread of the infection, and alleviated cytomegalovirus infection

Cited by 24 publications

References 36 publications

An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?

An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?

Chronic neurological diseases and COVID-19: Associations and considerations

Novel Therapeutics for Epstein–Barr Virus

Contact Info

Product

Resources

About